|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fitzmorris P, Shoreibah M, Anand BS and
Singal AK: Management of hepatocellular carcinoma. J Cancer Res
Clin Oncol. 141:861–876. 2015. View Article : Google Scholar
|
|
3
|
Imamura H, Matsuyama Y, Tanaka E, Ohkubo
T, Hasegawa K, Miyagawa S, Sugawara Y, Minagawa M, Takayama T,
Kawasaki S, et al: Risk factors contributing to early and late
phase intrahepatic recurrence of hepatocellular carcinoma after
hepatectomy. J Hepatol. 38:200–207. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bellavance EC, Lumpkins KM, Mentha G,
Marques HP, Capussotti L, Pulitano C, Majno P, Mira P,
Rubbia-Brandt L, Ferrero A, et al: Surgical management of
early-stage hepato-cellular carcinoma: Resection or
transplantation? J Gastrointest Surg. 12:1699–1708. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nakajima Y, Ko S, Kanamura T, Nagao M,
Kanehiro H, Hisanaga M, Aomatsu Y, Ikeda N and Nakano H: Repeat
liver resection for hepatocellular carcinoma. J Am Coll Surg.
192:339–344. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ge S and Huang D: Systemic therapies for
hepatocellular carcinoma. Drug Discov Ther. 9:352–362. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Daher S, Massarwa M, Benson AA and Khoury
T: Current and Future Treatment of Hepatocellular Carcinoma: An
Updated Comprehensive Review. J Clin Transl Hepatol. 6:69–78. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Swamy SG, Kameshwar VH, Shubha PB, Looi
CY, Shanmugam MK, Arfuso F, Dharmarajan A, Sethi G, Shivananju NS
and Bishayee A: Targeting multiple oncogenic pathways for the
treatment of hepatocellular carcinoma. Target Oncol. 12:1–10. 2017.
View Article : Google Scholar
|
|
9
|
Yu H, Pardoll D and Jove R: STATs in
cancer inflammation and immunity: A leading role for STAT3. Nat Rev
Cancer. 9:798–809. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nikolaou K, Sarris M and Talianidis I:
Molecular pathways: The complex roles of inflammation pathways in
the development and treatment of liver cancer. Clin Cancer Res.
19:2810–2816. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Subramaniam A, Shanmugam MK, Perumal E, Li
F, Nachiyappan A, Dai X, Swamy SN, Ahn KS, Kumar, Tan BK, et al:
Potential role of signal transducer and activator of transcription
(STAT)3 signaling pathway in inflammation, survival, proliferation
and invasion of hepatocellular carcinoma. Biochim Biophys Acta.
1835:46–60. 2013.
|
|
12
|
Wu WY, Li J, Wu ZS, Zhang CL, Meng XL and
Lobie PE: Prognostic significance of phosphorylated signal
transducer and activator of transcription 3 and suppressor of
cytokine signaling 3 expression in hepatocellular carcinoma. Exp
Ther Med. 2:647–653. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang CH, Xu GL, Jia WD, Li JS, Ma JL, Ren
WH, Ge YS, Yu JH, Liu WB and Wang W: Activation of STAT3 signal
pathway correlates with twist and E-cadherin expression in
hepatocellular carcinoma and their clinical significance. J Surg
Res. 174:120–129. 2012. View Article : Google Scholar
|
|
14
|
Mano Y, Aishima S, Fujita N, Tanaka Y,
Kubo Y, Motomura T, Taketomi A, Shirabe K, Maehara Y and Oda Y:
Tumor-associated macrophage promotes tumor progression via STAT3
signaling in hepatocellular carcinoma. Pathobiology. 80:146–154.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hettinghouse A, Liu R and Liu CJ:
Multifunctional molecule ERp57: From cancer to neurodegenerative
diseases. Pharmacol Ther. 181:34–48. 2018. View Article : Google Scholar
|
|
16
|
Ndubuisi MI, Guo GG, Fried VA, Etlinger JD
and Sehgal PB: Cellular physiology of STAT3: Where's the
cytoplasmic monomer? J Biol Chem. 274:25499–25509. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Eufemi M, Coppari S, Altieri F, Grillo C,
Ferraro A and Turano C: ERp57 is present in STAT3-DNA complexes.
Biochem Biophys Res Commun. 323:1306–1312. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chichiarelli S, Gaucci E, Ferraro A,
Grillo C, Altieri F, Cocchiola R, Arcangeli V, Turano C and Eufemi
M: Role of ERp57 in the signaling and transcriptional activity of
STAT3 in a melanoma cell line. Arch Biochem Biophys. 494:178–183.
2010. View Article : Google Scholar
|
|
19
|
Choe MH, Min JW, Jeon HB, Cho DH, Oh JS,
Lee HG, Hwang SG, An S, Han YH and Kim JS: ERp57 modulates STAT3
activity in radioresistant laryngeal cancer cells and serves as a
prognostic marker for laryngeal cancer. Oncotarget. 6:2654–2666.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Takata H, Kudo M, Yamamoto T, Ueda J,
Ishino K, Peng WX, Wada R, Taniai N, Yoshida H, Uchida E, et al:
Increased expression of PDIA3 and its association with cancer cell
proliferation and poor prognosis in hepatocellular carcinoma. Oncol
Lett. 12:4896–4904. 2016. View Article : Google Scholar
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Δ Δ C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
|
|
22
|
Ishino K, Kudo M, Peng WX, Kure S,
Kawahara K, Teduka K, Kawamoto Y, Kitamura T, Fujii T, Yamamoto T,
et al: 2-Deoxy-d-glucose increases GFAT1 phosphorylation resulting
in endoplasmic reticulum-related apoptosis via disruption of
protein N-glycosylation in pancreatic cancer cells. Biochem Biophys
Res Commun. 501:668–673. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu M, Du L, He Z, Yan L, Shi Y, Shang J
and Tang H: Increased ERp57 Expression in HBV-Related
Hepatocellular Carcinoma: Possible Correlation and Prognosis.
Biomed Res Int. 2017:12526472017.PubMed/NCBI
|
|
24
|
Ni M and Lee AS: ER chaperones in
mammalian development and human diseases. FEBS Lett. 581:3641–3651.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Corazzari M, Gagliardi M, Fimia GM and
Piacentini M: Endoplasmic reticulum stress, unfolded protein
response, and cancer cell fate. Front Oncol. 7:782017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bánhegyi G, Baumeister P, Benedetti A,
Dong D, Fu Y, Lee AS, Li J, Mao C, Margittai E, Ni M, et al:
Endoplasmic reticulum stress. Ann N Y Acad Sci. 1113:58–71. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Luo B and Lee AS: The critical roles of
endoplasmic reticulum chaperones and unfolded protein response in
tumorigenesis and anticancer therapies. Oncogene. 32:805–818. 2013.
View Article : Google Scholar
|
|
28
|
Ramírez-Rangel I, Bracho-Valdés I,
Vázquez-Macías A, Carretero-Ortega J, Reyes-Cruz G and
Vázquez-Prado J: Regulation of mTORC1 complex assembly and
signaling by GRp58/ERp57. Mol Cell Biol. 31:1657–1671. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hussmann M, Janke K, Kranz P, Neumann F,
Mersch E, Baumann M, Goepelt K, Brockmeier U and Metzen E:
Depletion of the thiol oxidoreductase ERp57 in tumor cells inhibits
proliferation and increases sensitivity to ionizing radiation and
chemotherapeutics. Oncotarget. 6:39247–39261. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Grillo C, D'Ambrosio C, Scaloni A,
Maceroni M, Merluzzi S, Turano C and Altieri F: Cooperative
activity of Ref-1/APE and ERp57 in reductive activation of
transcription factors. Free Radic Biol Med. 41:1113–1123. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sequeira VB, Rybchyn MS, Tongkao-On W,
Gordon-Thomson C, Malloy PJ, Nemere I, Norman AW, Reeve VE,
Halliday GM, Feldman D, et al: The role of the vitamin D receptor
and ERp57 in photoprotection by 1α,25-dihydroxyvitamin D3. Mol
Endocrinol. 26:574–582. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Krynetskaia NF, Phadke MS, Jadhav SH and
Krynetskiy EY: Chromatin-associated proteins HMGB1/2 and PDIA3
trigger cellular response to chemotherapy-induced DNA damage. Mol
Cancer Ther. 8:864–872. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Forbes SA, Beare D, Boutselakis H, Bamford
S, Bindal N, Tate J, Cole CG, Ward S, Dawson E, Ponting L, et al:
COSMIC: Somatic cancer genetics at high-resolution. Nucleic Acids
Res. 45(D1): D777–D783. 2017. View Article : Google Scholar :
|
|
34
|
Wang B, Ni Z, Dai X, Qin L, Li X, Xu L,
Lian J and He F: The Bcl-2/xL inhibitor ABT-263 increases the
stability of Mcl-1 mRNA and protein in hepatocellular carcinoma
cells. Mol Cancer. 13:982014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chen P, Hu T, Liang Y, Jiang Y, Pan Y, Li
C, Zhang P, Wei D, Li P, Jeong LS, et al: Synergistic inhibition of
autophagy and neddylation pathways as a novel therapeutic approach
for targeting liver cancer. Oncotarget. 6:9002–9017.
2015.PubMed/NCBI
|
|
36
|
Zhou M, Zhang Q, Zhao J, Liao M, Wen S and
Yang M: Phosphorylation of Bcl-2 plays an important role in
glycoche-nodeoxycholate-induced survival and chemoresistance in
HCC. Oncol Rep. 38:1742–1750. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zheng HC: The molecular mechanisms of
chemoresistance in cancers. Oncotarget. 8:59950–59964.
2017.PubMed/NCBI
|
|
38
|
Tai WT, Cheng AL, Shiau CW, Huang HP,
Huang JW, Chen PJ and Chen KF: Signal transducer and activator of
transcription 3 is a major kinase-independent target of sorafenib
in hepatocellular carcinoma. J Hepatol. 55:1041–1048. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Gu F-M, Li QL, Gao Q, Jiang JH, Huang XY,
Pan JF, Fan J and Zhou J: Sorafenib inhibits growth and metastasis
of hepato-cellular carcinoma by blocking STAT3. World J
Gastroenterol. 17:3922–3932. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Huang CY, Lin CS, Tai WT, Hsieh CY, Shiau
CW, Cheng AL and Chen KF: Sorafenib enhances radiation-induced
apoptosis in hepatocellular carcinoma by inhibiting STAT3. Int J
Radiat Oncol Biol Phys. 86:456–462. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
van Malenstein H, Dekervel J, Verslype C,
Van Cutsem E, Windmolders P, Nevens F and van Pelt J: Long-term
exposure to sorafenib of liver cancer cells induces resistance with
epithelial-to-mesenchymal transition, increased invasion and risk
of rebound growth. Cancer Lett. 329:74–83. 2013. View Article : Google Scholar
|
|
42
|
Tai WT, Cheng AL, Shiau CW, Liu CY, Ko CH,
Lin MW, Chen PJ and Chen KF: Dovitinib induces apoptosis and
overcomes sorafenib resistance in hepatocellular carcinoma through
SHP-1-mediated inhibition of STAT3. Mol Cancer Ther. 11:452–463.
2012. View Article : Google Scholar
|
|
43
|
Cicchillitti L, Della Corte A, Di Michele
M, Donati MB, Rotilio D and Scambia G: Characterisation of a
multimeric protein complex associated with ERp57 within the nucleus
in paclitaxel-sensitive and -resistant epithelial ovarian cancer
cells: The involvement of specific conformational states of
β-actin. Int J Oncol. 37:445–454. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Brierley JD, Gospodarowicz MK and
Wittekind C: TNM Classification of Malignant Tumours. 8th edition.
Wiley-Blackwell; New York, NY: 2016
|
